France-based pharma firm Servier is buying the muscular dystrophy enterprise of Edgewise Therapeutics as a part of a income progress technique in oncology and neurology. The deal brings an Edgewise drug in medical growth for 2 uncommon neuromuscular issues with restricted remedy choices.
The submit Servier Strikes Into Muscular Dystrophy, Paying $1.5B for Belongings From Edgewise Therapeutics appeared first on MedCity Information.